Hey researcher, what are you reading?

Research / 23 October 2019

Photo: Eli Francis on Unsplash

A UMC researcher reviews a book that examines the French pharmacovigilance system through the eyes of patients affected by adverse drug reactions.


I’ve just finished a fascinating book, Effets indésirables: Victimes des médicaments (undesirable effects: victims of drugs) by French freelance journalist, Clotilde Cadu, which delves into the French pharmacovigilance system through the eyes of patients affected by adverse drug reactions. It’s not so often that we come across books on pharmacovigilance themes for a broader audience, so it’s nice to find one as well written as this. 

Effets indésirables: Victimes des médicaments

In Effets indésirables: Victimes des médicaments, Cadu revisits several cases of drug-related harm from recent French history from the point of view of the patients. She gives the patients a voice, telling what it was like for those affected by the drugs and how they were perceived and treated by doctors, pharmaceutical companies, and the legal system. 

As a researcher, used to dealing with case reports, scientific papers, and statistics, a book like this is an important reminder that there is a real person behind every data point. I believe that keeping that perspective is vital to the quality and relevance of our research. The better we understand what the patients are experiencing, the better we can do our job of improving their safety.

 

Read more:

Sarah Watson
Research Pharmacist, UMC

You may also like


Beyond numbers, quality in ADR reporting – New podcast episode

Spontaneous adverse event reports pose significant challenges to pharmacovigilance scientists. How may we turn them into opportunities that benefit our pharmacovigilance systems?

04 June 2025

Uncovering pregnancy cases in VigiBase

To tackle the lack of medicine and vaccine safety data for pregnant people, UMC has developed an algorithm to more easily identify pregnancy-related reports in VigiBase.

21 January 2025

Artificial intelligence in pharmacovigilance: Harnessing potential, navigating risks

AI holds potential to transform pharmacovigilance. But navigating the risks requires critical assessment. This article explores AI's evolving role in medicines safety.

22 October 2024